22 results
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals, Inc.
9 May 23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
8:00am
commitment involving senior managers from FDA.
The MAESTRO-NASH registrational trial in noncirrhotic NASH has completed enrollment.
Patient recruitment
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals, Inc.
6 Aug 20
Madrigal Pharmaceuticals Reports 2020 Second Quarter
8:50am
recruitment rates, including opening new trial sites and enrolling patients with existing biopsies from NASH trials which were discontinued
424B5
rxl8b893sac
7 Jun 18
Prospectus supplement for primary offering
4:35pm
424B5
5tslq8ane0aqi23
6 Jun 18
Prospectus supplement for primary offering
12:00am
424B5
2qp1t9p 576zyq2va2rm
20 Dec 17
Prospectus supplement for primary offering
12:00am